Appendix 1 to the Joint Ministerial Order of Health and Food, Agriculture and Light Industry N ....dated on May ..., 2017

#### NATIONAL MULTI-SECTORIAL ACTION PLAN ON COMBATTING ANTIMICROBIAL RESISTANCE (2017-2020)

### **1. CURRENT CONTEXT**

Microbial infection and infectious disease prevalence among Mongolian population do not decrease and even has tendency to rise.

Linked to this situation, antibiotic use in medicine treatment is increasing year by year, several clans of microorganisms are getting resistant to antibiotics, and medical treatment is becoming challenging.

In other way, doctors do not take attention on a laboratory validation and do not have an interest to send patients for testing due to poor hospital laboratory settings especially insufficient capacity of microbiological laboratory, poor quality, somehow not reliable results and not available rapid test results.

Doctors usually have poor justification for antibiotic prescribing and there is a lack of control on prescribing, dispensing per prescription at pharmacy and use of antibiotics. Moreover knowledge and attitude of people is not sufficient, wrong practice to get antibiotics from pharmacy without any restriction and careless use of it widely spread among the population.

Mongolia imports 70 percent of total medicines from foreign countries and about 30 percent of total of the medicines used in treatment are antimicrobials. There are functioning about 35 local manufacturers and five of them producing antibiotics.

With the purpose of prevention of AMR, certain actions required to be taken including responsible prescribibg of antimicrobials, promoting distribution of antibiotics with doctor's prescription; to improve hospital capability for prevention and control of AMR; to improve awareness of patients, consumers and healthcare professionals about consequences of AMR and promoting rational use of medicines.

Mongolia has high consumption amount of animal products particularly meat. It has 3 million people and 50 million livestock. Recent years, consumption of imported chicken, sea food and pork is increasing. Today about 700 medicines

are registered and commonly used in the agriculture sector and it is vital to take a laboratory test and to ensure quality and safety of animal products consumed. Consumption of animal products with residual antibiotics is causing health risks through food products.

## 2. BACKGROUND

In order to make a proper decision in antibiotic use and emergence of antimicrobial resistance, strategic policy on rational use of antibiotics and antibacterial drugs should be developed in accordance to global strategy as a first step of action.

One of the worldwide emerging problems related to hospital quality care is a drug resistance particularly bacterial resistance to antibiotics and inappropriate combat to hospital acquired infections. Results from previous studies indicate that inappropriate use of antimicrobials, consequently the resistance to antimicrobials has been increasing in the last years.

According to the latest reports, resistance to third generation cephalosporins was 86/101 (85%) for *E coli*, 87/99 (88%) for *K.Pneumonia*, 42/75 (56%) for *N.gonorrhoeae*, 85/99 (86%) for *Methicillin-resistant S.aureus (MRSA)*; resistance to penicillins was 67/97(69%) for *S.pneumonia* and resistance to fluorquinolones - 68/91 (75%) for non-typhoid Salmonella and 35/57 (61%) for *Shigella spp* (Antimicrobial resistance, Global Report on Surveillance, World Health Organization, 2014)

Reports produced by the National Centre for Communicable Diseases of Mongolia indicated that out of 1495 isolates resistance to ampicillin was 100% for *E.Coli, Citrobacter freundii,* 80% for *Shigella,* 60% for *Staphylococcus,* 54% for *Streptococcus,* resistance to oxacillin was 15% for *Streptococcus,* respectively. (Microbiology laboratory of the National Centre for Communicable Diseases of Mongolia, report, 2014)

Therefore, there is an emerging need to develop an antibiotic treatment policy in detail, to take actions in drug treatment, to streamline rational use of antibacterial drugs, and to monitor antimicrobial resistance based on the above mentioned evidences.

In addition, improvement of human resource and laboratory capacity of human and animal sector, as well as information exchange at the worldwide level is essential.

World Health Organization recommends its member countries to develop a multisectoral National Action Plan on prevention of AMR and implement corresponding activities.

# 3. GOVERNANCE

A working group consisting of non cadre members representing the health, food and agriculture sector will be discussing about antimicrobial resistance. Technical working group will discuss about the process of implementation at the end of year, annually.

Terms of reference of working group:

- Responsible for implementation of activities in the corresponding sectors and agencies
- Meet every six months to review and coordinate implementation
- M&E of the implementation of the national action plan
- Organize technical meetings on specific issues when needed
- Provide technical input on activities

## 4. MAIN PRINCIPLES

The National Action Plan on Combatting Antimicrobial Resistance will be applied for all health-care facilities including public and private health care organizations, as well as veterinary clinics and animal husbandry with main principles of their active participation, open to public and be responsible including:

- 4.1 approach and improve coordination of AMR at international and national levels;
- 4.2 to promote prevention first through improved laboratory capacity for AMR surveillance and diagnostics, and infection prevention and control measures;
- 4.3 to improve monitoring of prescribing and dispensing of antibiotics in all health care facilities and veterinary clinics for consumers, and streamline rational use of antibiotics;
- 4.4 to ensure access to quality assured antimicrobials through conduct post marketing surveillance of antimicrobial drugs regularly;
- 4.5 to foster research and development for new tools to combat AMR.

# 5. OBJECTIVE(S)

The goal of the National Action Plan is to promote rational use of antibiotics and prevention of the emergence and spread of AMR, improve surveillance of AMR and diagnostics, treatment of antimicrobial infections, and enhance quality of hospital care and outcomes.

The National Action Plan includes activities in accordance with the following six areas:

- 1. Establish a governance and ensure multisectoral role to combat antimicrobial resistance, sustainable investment and functioning
- 2. Strengthen surveillance and diagnostic capacity for AMR and research
- 3. Reduce the spread of infections through better infection prevention and control
- 4. Ensure quality and safety of antimicrobial medicines
- 5. Optimize the use of antimicrobials in the human and animal sectors
- 6. Raise awareness and understanding of AMR and rational use of the general public, herdsmen and health professionals

### 6. Operational action plan

|     |   |      | Ye   | ear  |      |   | Participating                 |   |
|-----|---|------|------|------|------|---|-------------------------------|---|
|     | Activities  | 2017 | 2018 | 2019 | 2020 | Leading<br>Implementer(s)                       | organization<br>(s)           | Indicator(s)  |
|     | 1. Establish an multisectoral coor  | dina | ting | me   | chai | nism to combat A                                | MR, improve le                | gal environment   |
| 1.1 | Set up a Technical Working Group<br>to coordinate the implementation<br>of the national action plan and<br>discuss every six mounts about the<br>implementation | x    | x    | x    | x    | MoH<br>MoFALI                                   | Participating<br>stakeholders | Technical Working Group to coordinate<br>the implementation of the national<br>action plan in MoH and MoFALI<br>established |
| 1.2 | Sharing information about new<br>registered and rectricted<br>antimicrobials by human and<br>animal drug committies semi-<br>annually                           | x    | x    | x    | x    | Human Drug<br>Council<br>Animal Drug<br>Council | MoH<br>MoFALI<br>CHD          | Mechanism to link the human and<br>animal drug committees with regular<br>information of antimicrobials<br>established.     |
| 1.3 | Upgrade legal environment in Law<br>on Medicines and Medical Devices<br>regarding to prescription only<br>medicines for human and animal<br>use                 | x    | x    | x    | X    | MoH<br>MoFALI                                   | GASI                          | Legal environment regarding to prescription only medicines for human and animal use upgraded.                               |
| 1.4 | Estimate the annual expenditure<br>of activities in the plan and involve<br>in budget of all participating<br>organizations                                     | x    | x    | x    | x    | Participating organizations                     | MoH<br>MoFALI<br>EFD          | Annual expenditure of activities<br>estimated in the plan and involved in<br>budget of all participating organizations.     |

| 1.5 | Overall implementation of the plan<br>to be reviewed jointly by the<br>Ministries  |   |   |   | x | MoH,<br>MoFALI                      | CHD, VABA  | Overall implementation of the plan<br>reviewed by M&E and internal auditing<br>departments in each Ministry.   |
|-----|--|---|---|---|---|-------------------------------------|--|--|
| 1.6 | Hold bi-annual National AMR<br>conference to share information<br>including the national AMR<br>surveillance report , determine<br>next steps for the action   |   | x |   | x | Technical<br>working group<br>(TWG) | MoH,<br>MoFALI,<br>WHO,<br>FAO, OIE                    | Bi-annual National AMR conference<br>organized.  |
| 1.7 | Promote sharing of information<br>from the human animal sector<br>through relevant journals, establish<br>each quarter reporting mechanism<br>to AMR multi sectorial working<br>group, TWG and related<br>stakeholders | x | x | x | x | NCCD, CHD,<br>VABA,                 | MoH,<br>MoFALI,<br>WHO,<br>FAO,<br>OIE                 | Sharing of information from the human<br>animal sector through relevant journals<br>promoted, reported and disseminate to<br>the AMR multi sectorial working group,<br>TWG and relevant stakeholders<br>quarterly. |
| 1.8 | Set up a coordinating mechanism<br>to analyze the national AMR data<br>with dedicated staff with job<br>description  |   | x | x | X | NCCD,<br>VABA                       | MoH,<br>MoFALI,<br>SCVL,<br>NVDTCL<br>WHO, FAO,<br>OIE | Coordinating mechanism to analyze the national AMR data established at NCCD and VABA with dedicated staff with job description.  |

| 1.9    | Include in Law of animal health<br>issue of control of drug residue in<br>raw materials and products<br>derived animals  | X    |      |        |       | MoFALI           | SCVL, NGOs  | Issue of control of drug residue in raw materials and products derived animals included in Law of animal health.   |
|--------|--|------|------|--------|-------|------------------|---|--|
| 1.10   | Develop a national program on<br>food safety and quality including<br>the determination of antimicrobial<br>residues in food products and<br>implement the program |      | x    | x      | x     | MoFALI           | Vet Ins,<br>NGOs  | Program developed and implemented.   |
| 2. Str | engthen surveillance and diagnost  | ic c | apac | city f | for A | MR and resea     | arch  | I  |
| 2.1    | Develop a national guideline on<br>determination and surveillance of<br>AMR based on international<br>accepted guidelines and the WHO<br>AMR surveillance manual   |      | x    |        |       | NCCD,<br>Vet Ins | MoH, MoFALI,<br>NZCD, NCPH,<br>CHD, WHO,<br>FAO, OIE  | National guideline on determination and surveillance of AMR developed.   |
| 2.2    | Strengthen, update and harmonize<br>microbiology identification SOPs<br>for AST and AMR in human and<br>animal laboratories  | x    | x    | x      | x     | NCCD, Vet<br>Ins | MNUMS,<br>laboartories of<br>selected II, III<br>hospitals of<br>aimags and<br>districts and<br>animal<br>laboratories,<br>WHO, ADB,<br>FAO | Mcrobiology identification SOPs for AST<br>and AMR in human and animal<br>laboratories strengthened and<br>implemented in selected hospitals and<br>animal laboratories. |

| 2.3 | Prepare training materials,<br>distribute and conduct hands on<br>and e-learning trainings on the use<br>of the AMR surveillance manual<br>and standardized SOPs in all<br>laboratories (human and animal) | x | x | x | x | NCCD,<br>Vet Ins       | MoH, MoFALI,<br>GASI, NZCD,<br>VABA, NGOs,<br>AFCCP,<br>Academic<br>Institutions<br>WHO, OIE,<br>FAO | Training materials, distribute and<br>conduct hands on and e-learning<br>trainings on the use of the AMR<br>surveillance manual and standardized<br>SOPs in all laboratories (human and<br>animal). |
|-----|--|---|---|---|---|------------------------|--|---|
| 2.4 | Invite WHO expert on AMR in<br>order to enroll into the Global AMR<br>Surveillance System (GLASS) and<br>conduct trainings for human and<br>animal laboratories  | x |   |   |   | МоН                    | NCCD, NCZD,<br>Vet Ins, NCPH,<br>CHD, human and<br>animal<br>laboratories                            | Training conducted.   |
| 2.5 | Enroll into the Global AMR<br>Surveillance System (GLASS,<br>WHONET) and upload hospital<br>laboratory data regularly in human<br>and animal laboratories  | x | x | x | x | NCCD,<br>Vet Ins       | Human and<br>animal<br>laboratories,<br>TB lab, NCZD   | Human and animal laboratories enrolled<br>into the Global AMR Surveillance<br>System (GLASS, WHONET) and<br>uploadad hospital laboratory data<br>regularly.   |
| 2.6 | Upgrade national WHONET<br>network to aimags, districts,<br>private hospitals laboartories and<br>NZDC   | x | x |   |   | NCCD, Vet<br>Ins       | Aimags, district,<br>private hospitals<br>laboartories and<br>NCZD,<br>WHO, OIE,FAO                  | Aimags, districts, private hospitals<br>laboartories and NZDC lab linked to<br>WHONET.  |
| 2.7 | Identify priority resistant<br>pathogens transmitting from<br>veterinary to human sector based<br>on local and global antimicrobial  | x |   |   |   | NCCD, Vet<br>Ins, NCZD | MoH, MoFALI,<br>GASI WHO,<br>OIE,FAO   | Priority resistant pathogens transmitting<br>from veterinary to human sector<br>identified.   |

|      | surveillance data   |   |   |   |   |   |  |  |
|------|---|---|---|---|---|---|--|--|
| 2.8  | Strengthen infstructure, lab<br>equipments and reagents of<br>microbiological laboratories to<br>meet standard requirements in<br>cascade   | x | x | x | x | Aimags,<br>districts<br>hospitals<br>laboartories                           | MoH, WHO, ADB                          | Infstructure, lab equipments and<br>reagents of selected microbiological<br>laboratories strengthened to meet<br>standard requirements.  |
| 2.9  | Accredite human and animal<br>laboratories in cascade and set up<br>mechanism to improve<br>proficiency testing   | x | X | X | X | NCCD, Vet<br>Ins, human<br>and animal<br>lab                                | MASM, human<br>and animal lab,<br>NGOs | Selected human and animal laboratories accredited and improved proficiency testing.  |
| 2.10 | Enroll in external quality<br>assurance programme from<br>UKNEQAS or other European<br>providers/networks (e.g. ECDC)   | x | X | x | x | NCCD, Vet<br>Ins, NCZD  | MoH, MoFALI,<br>WHO, FAO, OIE          | Human and animal laboratories enrolled<br>in external quality assurance<br>programme from UKNEQAS/ECDC   |
| 2.11 | Improve capacity of TB reference<br>laboratory in line with AMR<br>surveillance   | x | x |   |   | TB<br>reference<br>laboratory   | MoH, Global<br>Fund                    | Capacity of TB reference laboratory improved   |
| 2.12 | To increase the number of<br>laboratories capable of early and<br>rapid detection of antimicrobial<br>resistance by means of molecular<br>biological level in regards with<br>tuberculosis and rifampicin | x | x | x | x | RDTC,<br>Hospitals'<br>DTC,<br>aimags, and<br>districts' TB<br>laboratories | MoH, Global<br>Fund                    | The number of laboratories capable of<br>early and rapid detection of<br>antimicrobial resistance by means of<br>molecular biological level in regards with<br>tuberculosis and rifampicin |
| 2.13 | Identify and locate opportunities to<br>introduce rapid detection method<br>for AST   |   | x | x | x | FCH, TCH  |  | Rapid method for determination of AST introduced.  |

|     |  |   | T | 1 |   |   |  |  |
|-----|--|---|---|---|---|---|--|--|
| 3.1 | Undertake assessment of IPC knowledge, attidue, and practice (KAP) among health professionals  |   | x | x |   | Research<br>organization/<br>team, NGOs | NCPH, CHD,<br>MoH, AFCCP,<br>ADB, WHO                  | Assessment conducted, recommendations disseminated.  |
| 3.2 | Conduct regular trainings on<br>strengthening IPC among health<br>professionals based on results of<br>the assessment                        | x | x | x | x | NCCD,<br>Academic<br>organizations      | NCPH, CHD,<br>MoH,<br>ADB, WHO                         | Trainings conducted.   |
| 3.3 | Develop IPC training and<br>communication materials based on<br>results of KAP survey of health<br>professionals, publish and<br>disseminate |   | x | x | x | CHD, NCPH,<br>NGOs                      | MoH,<br>ADB, WHO                                       | IPC training and communication<br>materials based on results of KAP<br>survey of health professionals<br>developed, published and disseminated.              |
| 3.4 | Strengthen guidelines on active<br>surveillance linked to main hospital<br>acquired infections and implement                                 | x | x |   |   | NCCD,<br>FiHCDP                         | MoH, ADB   | Guidelines on active surveillance linked<br>to 4 main hospital acquired infections<br>developed, approved and implemented<br>(in 2017 8, 2018- 11 hospitals) |
| 3.5 | Implement active surveillance of<br>hospital acquired infections in<br>aimags' and districts' hospitals<br>step by step                      | x | x | x | x | NCCD,<br>FiHSDP                         | MoH, HDs of<br>capital city and<br>aimags, ADB,<br>WHO | Active surveillance of hospital acquired<br>infections implemented in aimags' and<br>districts' hospitals  |
| 3.6 | Develop job description of hospital<br>epidemiologist and infection<br>disease specialist and get  | x | x |   |   | NCCD,<br>hospitals                      | MoH, ADB   | Job description of hospital<br>epidemiologist and infection disease<br>specialist developed and approved.  |

|      | approval   |   |   |   |   |                            |  |   |
|------|--|---|---|---|---|----------------------------|--|---|
| 3.7  | Create a national surveillance and<br>information system for infectious<br>diseases  |   |   | x | x | MoH, CHD,<br>NCCD,<br>NCZD | Capital city's<br>HD, aimags'<br>and capital city's<br>HDs | National surveillance and information system for infectious diseases created.   |
| 3.8  | Study identification of the antmicrobial resistance  |   |   | x | x | MoH,<br>NCCD,<br>NCZD      | Vet Ins<br>Donor<br>organizations                          | Study report.   |
| 3.9  | Develop and comply with the<br>revised regulations in regards with<br>the prevention, detection and<br>surveillance of resistant isolates  |   | x | x | x | NCCD,<br>NCPH              | MoH, hospitals<br>WHO                                      | Regulation procedure approved and implemented.  |
| 3.10 | Improve the centralized<br>sterilization of hospitals and<br>equipment, tools with high risk of<br>infection (lenses, respiratory<br>apparatus) in compliance with the<br>standards  | x | x | x | x | Hospitals                  | MoH, FiHSDP,<br>ADB, WHO                                   | Centralized sterilization of hospitals and<br>equipment, tools with high risk of<br>infection (lenses, respiratory apparatus)<br>improved in compliance with the<br>standards.        |
| 3.11 | Strengthen the infection<br>prevention and control system in<br>health care facilities, introduce an<br>implementation plan of newest and<br>modest technology of waste<br>management and provide modern<br>sterilization and disinfection |   | x | x | x | NCCD,<br>hospitals         | MoH, aimags'<br>and capital city's<br>HDs                  | Implementation plan of newest and<br>modest technology of waste<br>management introduced and modern<br>sterilization and disinfection equipment<br>provided in healh care facilities. |

|       | equipment and tools step by step   |      |      |      |      |                           |                                   |   |
|-------|--|------|------|------|------|---------------------------|-----------------------------------|---|
| 3.12  | To update IPC guidelines for<br>animal husbandry based on<br>international guidelines  | x    | x    | x    | x    | Vet Ins                   | MoFALI, FAO,<br>OIE               | IPC guidelines for animal husbandry based on international guidelines   |
| 4. Er | nsure quality and safety of antimic  | robi | al m | edic | ines | ;                         |                                   |   |
| 4.1   | Update, get approval and<br>disseminate Essential Medicines<br>List  | x    |      |      | x    | МоН                       | MoH,<br>Profeesional<br>Committee | Essential Medicines List updated and disseminated   |
| 4.2   | Develop and comply with<br>procedures on recalling<br>medicines, bio preparations,<br>medical devices, biologically active<br>compounds and corresponding<br>raw materials, starting materials<br>from market, withdraw, abolish,<br>re-working and re- licensing such<br>products to the market |      | x    | x    | x    | МоН                       | GASI, CHD                         | Legal aspects on recalling medicines,<br>bio preparations, medical devices and<br>biologically active compounds from<br>market established and implemented. |
| 4.3   | Set up mechanism that<br>bioequivalence determination<br>should be one the criteria for<br>registration of generic<br>antimicrobials   | x    | x    | x    | x    | HDC,<br>CHD               | MoH, GASI, DCL                    | Bioequivalence determination- one the criteria for registration of generic antimicrobials.  |
| 4.4   | Develop methodology for<br>determination of bio potency of<br>antibiotics by microbiological   | x    | x    | x    | x    | Human<br>pharmacop<br>eia | DCL, MNUMS                        | Methodology of determination of bio<br>potency of antibiotics by microbiological<br>method developed.   |

|      | method and conduct test regularly  |   |   |   |   | committee  |   |   |
|------|--|---|---|---|---|--|---|---|
| 4.5  | Conduct post marketing<br>surveillance of antibiotics quality<br>and safety  | x |   | x |   | Human<br>pharmaco-<br>peia<br>committee,<br>Research<br>team | GASI, DCL,<br>MNUMS, Drug<br>manufacturers<br>and importers | Post marketing surveillance of antibiotics quality and safety conducted.                              |
| 4.6  | Study prevalence of substandard,<br>illegal medicines (including<br>antimicrobilas) in drug market   | x |   |   |   | Research<br>team   | MoH, ADB,<br>Technical<br>Assistant Project                 | Prevalence of substandard, illegal<br>medicines (including antimicrobilas) in<br>drug market studied. |
| 4.7  | Develop national "Antimicrobial<br>guidelines" based on local<br>antibiograms and international<br>guidelines and comply with  | x | x | X | x | FCH, SCH,<br>TCH,<br>NCCD,<br>MNUMS                          | MoH, CHD, WHO   | "Antimicrobial guidelines" based on local antibiograms developed and complied.                        |
| 4.8  | Disseminate antimicrobial<br>guidelines to all hospitals and hold<br>regular training workshops (hands<br>on and e-learning) on the use of<br>the guidelines with health-care<br>professionals | x | x | x | x | Hospitals,<br>academic<br>institutions                       | Health care<br>facilities, WHO                              | Hands on and e-learning trainings on<br>the use of the "Antimicrobial<br>guidelines"provided.         |
| 4.9  | Develop hospital antibiotic<br>resource policy and set up<br>mechanism to register the<br>medicines included in the hospital<br>resource policy  |   | x | x | x | SCH, NGO-<br>hospital<br>association                         | MoH, CHD, Em<br>Association,<br>WHO                         | Hospital antibiotic resource policy developed and priority antibiotics registered.                    |
| 4.10 | Ensure manufacturing of<br>antimicrobials are compliant with<br>GMP  | x | x | x | x | MoH, drug<br>manufactur<br>ers                               | GASI, Em<br>association                                     | Drug manufacturers producing<br>antimicrobials complied with GMP<br>standard.                         |

| 4.11  | Develop and implement enforce<br>regulation on prescription only<br>dispensing medicines, including<br>antibiotics  | x   | x   | x   | X   | CHD, MoH        | GASI, hospitals, pharmacies  | Enforce regulation on prescription only sales medicines, including antibiotics approved and implemented.               |
|-------|---|-----|-----|-----|-----|-----------------|--|--|
| 4.12  | Strengthen capacity of GASI<br>inspectors regarding to<br>enforcement implementation of<br>AMR issue  | x   | х   | x   | Х   | GASI            | MoH, MoFALI,<br>Donor<br>organizations   | Inspectors GASI trained, capacity improved.  |
| 5. Oj | otimize the use of antimicrobials in  | the | hun | nan | and | animal sector   | S  |  |
| 5.1   | Revise and update drug<br>registration procedure in human<br>and animal sector  | x   |     |     |     | HDC, ADC        | MoH, MoFALI  | Drug registration procedure in human<br>and animal sector updated and<br>approved.                                     |
| 5.2   | Develop country specific<br>antimicrobial consumption (AMC)<br>methodology and programme for<br>human animal health   | x   |     |     |     | MoH,<br>MoFALI  | CHD, NCPH,<br>VABA, research<br>institutions   | Country specific antimicrobial<br>consumption (AMC) methodology and<br>programme for human animal health<br>developed. |
| 5.3   | Collect AMC data and develop<br>annual report for human and<br>animal health sector   |     | x   | x   | X   | MoH,<br>MoFALI  | WHO, FAO, OIE  | AMC data collected and annual report<br>for human and animal health sector<br>developed.                               |
| 5.4   | Conduct ongoing awareness<br>raising activities on rational use of<br>antimicrobials and risks of AMR<br>for human and animal<br>sector,health care professioanals,<br>general public and herdsmen<br>within WAAW | X   | x   | x   | x   | MoH,<br>MoAFLI, | CHD, VABA,<br>AFCCP, GASI,<br>donor<br>organizations,<br>Professional<br>Assiciasions,<br>NGOs | Awareness raising activities<br>on rational use of antimicrobials and<br>risks of AMR conducted.                       |

| 5.5  | Expand existing interactive training<br>materials on appropriate use of<br>antimicrobials and AMR for health<br>care professionals  |   | X | x | x | MNUMS                                      | CHD, hospitals  | Existing interactive training materials on<br>appropriate use of antimicrobials and<br>AMR expanded and training with credit<br>hour for health care professionals<br>provided.                     |
|------|---|---|---|---|---|--|---|---|
| 5.6  | Conduct one month campaing on<br>rational use of antibiotics in<br>hospitals according to specific<br>schedule every year   | x | X | x | X | CHD  | Health care<br>facilities in UB   | One month campaing on rational use of<br>antibiotics conducted in II and III levels<br>hospitals during a year and reports of<br>activities done.   |
| 5.7  | Develop and implement a<br>national AMS guideline for<br>selected hospitals   | x |   |   |   | FCH, TCH,<br>hospitals<br>DTCs             | MoH, MNUMS,<br>WHO  | National AMS guideline in selected 2<br>hospitals developed, implemented and<br>disseminated to other hospitals.  |
| 5.8  | Develop and implement standards<br>on prescription and prescribing of<br>veterinary medicines   | x | Х | x | x | Animal<br>Pharmaco-<br>peia<br>Committee   | MoFALI, ADC   | Standards on prescription and prescribing of veterinary medicines developed and implemented.  |
| 5.9  | Develop interactive training<br>module on rational use of drugs<br>and AMR in animal sector   |   |   | x |   | Vet Ins,<br>Academic<br>institutions       | MoFALI, Donor organizations   | Interactive training module on rational use of drugs and AMR in animal sector developed.  |
| 5.10 | Provide and evaluate regular<br>training on developed interactive<br>training module on rational use of<br>drugs and AMR in animal sector<br>for vets and specialists of animal<br>sector |   |   | x | x | Vet Ins,<br>Academic<br>organiza-<br>tions | AFCCP, Entities,<br>Professional org,<br>NGOs, vets,<br>veterinary<br>pharmacists | Regular training on developed<br>interactive training module on rational<br>use of drugs and AMR in animal sector<br>for vets and specialists of animal sector<br>provided and trainings evaluated. |

| 5.11  | Assess and strengthen<br>inspection law implementation on<br>enforcement of regulation of<br>prescription only sales of<br>antimicrobials  | X    |      |     |       | CHD, VABA  | MoH, MoFALI,<br>GASI, AFCCP  | Assessment report, correct actions done.   |
|-------|--|------|------|-----|-------|--|--|--|
| 6.Rai | se awareness and understanding of  | of A | MR a | and | ratio | onal use of the                                    | e general public, he   | erdsmen and health professionals   |
| 6.1   | Promote activities to expand<br>activities for increasing number of<br>reimbursed prescription antibiotics   |      |      |     |       | CHD  | SIGA, Hospitals,<br>Em association,<br>Association of<br>FGPs, AFCCP | Number of reimbursed antibiotics increased.  |
| 6.2   | Publish all health care facilities<br>prescription form in sufficient<br>number, provide monitoring control<br>of suplly of prescription forms<br>regularly                          | x    | x    | x   | x     | Health care<br>facilities,<br>CHD                  | Em association,<br>Association of<br>FGPs, AFCCP,<br>GASI            | All health care facilities prescription form in sufficient number.   |
| 6.3   | Conduct KAP surveys of the general public and hersdsmen on AMR and rational use drugs  | x    |      | x   |       | NCPH   | CHD, AFCCP,<br>NGOs, Academic<br>Institutions                        | Asssessment reports completed, recommandations done.   |
| 6.4   | Develop and disseminate via<br>public media IEC materials,<br>posters, short videos ect on AMR<br>and rational use drugs for general<br>public, herdsmen and health<br>professionals | x    | x    | x   | x     | NCPH,<br>CHD,<br>Agriculture<br>Science<br>Academy | MoH, MoFALI,<br>GASI, AFCCP,<br>Professional org,<br>NGOs            | IEC materials, posters, short videos ect<br>on AMR and rational use drugs for<br>general public, herdsmen and health<br>professionals developed, disseminated<br>via public media. |
| 6.5   | Comment to introduce rational use  | х    |      |     |       | MoH, CHD   | MoECSS   | Rationale of introduction of rational use  |

|      | of drugs and risks of AMR<br>module/tool into secondary school<br>curriculum  |   |   |   |   |   |   | of drugs and risks of AMR module into secondary school curriculum commented.   |
|------|---|---|---|---|---|---|---|--|
| 6.6  | Organize actions to involve into<br>awareness raising activities on<br>rational use of drugs and AMR<br>governmental, NGOs, public<br>media tools (TV, FM, facebook,<br>twitter), journalists ect | x | x | x | x | AFCCP,<br>TWG   | MoH, MoFALI,<br>NGOs, public<br>media     | Governmental, non governmental<br>organizations, public media tools,<br>journalists involved into awareness<br>raising activities on rational use of drugs<br>and AMR. |
| 6.7  | Information sharing about AMP in human and health sector via professional journals  | x | x | x | x | CHD,<br>Vet Ins,<br>NGOs  | MoH, MoFALI                               | Information sharing about AMP in human and health sector via professional journals provided.   |
| 6.8  | Determine the economic burden related to AMR and inform all stekeholders  | x | x |   |   | NCCD, Vet<br>Ins, NCPH,<br>CHD,<br>MNUMS                            | MoH, MoFALI,<br>WHO, FAO,OIE              | The economic burden related to AMR determined and informed to relevant stakeholders.   |
| 6.9  | Develop training material and<br>conduct regular tranings on<br>rational use of medicines, AMR<br>and prescription for FGPs, soums<br>and bags health care spesialists<br>and evaluate trainings  | x | x | x | x | FGPs<br>Association,<br>Acadermic<br>institutions                   | NCPH, CHD                                 | Traning materai on rational use of<br>medicines, AMR and prescription for<br>FGPs, soums and bags health care<br>spesialists prepared and the specialist<br>trained.   |
| 6.10 | Promote to provide specific<br>activities on dispencing<br>prescription only antibiotics for<br>pharmacies  | X | x | x | x | "Em"<br>association,<br>Association<br>of veterinary<br>pharmacists | Aimags,districts<br>health<br>departments | Specific activities on dispencing<br>prescription only antibi otics for<br>pharmacies organized and all<br>pharmacies complied with.                                   |

| 6.11 | Translate , publish and                     | х | Х | Professional | ,             | Sanford Guide to Antimicrobial Therapy              |
|------|---|---|---|--------------|---------------|---|
|      | disseminate key technical                   |   |   | association  | organizations | 2016 46 <sup>th</sup> edition translated, published |
|      | documents to support decision               |   |   | SCH          |               | and distributed.                                    |
|      | making -Sanford Guide to                    |   |   |              |               |   |
|      | Antimicrobial Therapy 2016 46 <sup>th</sup> |   |   |              |               |   |
|      | edition                                     |   |   |              |               |   |